Mulgrew, Kathy
1Early Oncology R&D, AstraZeneca.
3 papers on CoChatORCID 0000-0001-9977-7597
Most cited papers
- Verified
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
Dovedi, S. J., Elder, M. J., Yang, C., Sitnikova, S. I., Irving, L., Hansen, A., Hair, J., Jones, D. C., Hasani, S., Wang, B., et al. (2021) · Cancer Discovery
Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research
Cited by 186
- Verified
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Pore, N., Wu, S., Standifer, N., Jure-Kunkel, M., de los Reyes, M., Shrestha, Y., Halpin, R., Rothstein, R., Mulgrew, K., Blackmore, S., et al. (2021) · Cancer Discovery
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 88
- Verified
Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
Lutterbuese, R., Raum, T., Kischel, R., Lutterbuese, P., Schlereth, B., Schaller, E., Mangold, S., Rau, D., Meier, P., Kiener, P. A., et al. (2009) · Journal of Immunotherapy
Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and Immunotoxins
Cited by 77
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free